A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction-Reference-Cited by-同舟云学术

A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction

Published:2010-01 Issue:1 Volume:21 Page:71-77
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Moehler M.,Kanzler S.,Geissler M.,Raedle J.,Ebert M.P.,Daum S.,Flieger D.,Seufferlein T.,Galle P.R.,Hoehler T.

Funder

Roche and Pfizer

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/21/1/71/338071/mdp269.pdf

Reference39 articles.

1. Incidence and mortality from stomach cancer in Japan, Slovenia and the USA;Lambert;Int J Cancer,2002

2. Cancer Incidence in Five Continents, Vol. VIII;Parkin,2002

3. Cancer statistics, 2005;Jemal;CA Cancer J Clin,2005

4. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data;Wagner;J Clin Oncol,2006

5. Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up;Cunningham;Ann Oncol,2008

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry;Clinical and Translational Oncology;2024-02-15

2. Palliative Chemotherapy in Advanced or Metastatic Gastric Cancer. IX-1. Overview and Cytotoxic Agents;Gastrointestinal Cancer;2023

3. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2022-02

4. Case studies highlighting the multiple facets of gastric cancer: one diagnosis, multiple approaches;Research and Clinical Applications of Targeting Gastric Neoplasms;2021

5. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2019-07